Trial · NCT04577820
Registered outcomes41
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 41
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of treatment-emergent adverse event (TEAEs) | Through week 28 | |
| Primary | Number of new HO lesions as assessed by CT | At week 28 | |
| Secondary | Total volume of new HO lesions as assessed by CT | At week 28 | |
| Secondary | Number of new HO lesions as assessed by positron emission tomography (PET) | At week 28 | |
| Secondary | Total lesion activity in new HO lesions as assessed by PET | At week 28 | |
| Secondary | Percent of patients with new HO lesions as assessed by CT | At week 28 | |
| Secondary | Percent of patients with new HO lesions as assessed by PET | At week 28 | |
| Secondary | Percent of patients with investigator-assessed flare-ups | Baseline to week 28 | |
| Secondary | Percent of patients with investigator-assessed flare-ups | Baseline to week 56 | |
| Secondary | Percent of patients with flare-ups assessed by patient e-diary | Baseline to week 28 | |
| Secondary | Percent of patients with flare-ups assessed by patient e-diary | Baseline to week 56 | |
| Secondary | Number of new HO lesions as assessed by CT | At week 56 | |
| Secondary | Total volume of new HO lesions as assessed by CT | At week 56 | |
| Secondary | Percent of patients with new HO lesions as assessed by CT | At week 56 | |
| Secondary | Number of new HO lesions as assessed by PET | At week 56 | |
| Secondary | Total lesion activity in new HO lesions as assessed by PET | At week 56 | |
| Secondary | Percent of patients with new HO lesions as assessed by PET | At week 56 | |
| Secondary | Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET | Baseline and week 28 | |
| Secondary | Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET | Baseline and week 56 | |
| Secondary | Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET | Baseline and week 28 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04577820/registered